Fuji Pharma Co. Ltd
Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women, in vitro diagnostics, acute medical care products, and curative medicines, and information regarding pharmace… Read more
Fuji Pharma Co. Ltd (FUP) - Total Assets
Latest total assets as of September 2025: €93.41 Billion EUR
Based on the latest financial reports, Fuji Pharma Co. Ltd (FUP) holds total assets worth €93.41 Billion EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Fuji Pharma Co. Ltd - Total Assets Trend (2014–2025)
This chart illustrates how Fuji Pharma Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Fuji Pharma Co. Ltd - Asset Composition Analysis
Current Asset Composition (September 2025)
Fuji Pharma Co. Ltd's total assets of €93.41 Billion consist of 51.3% current assets and 48.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 7.8% |
| Accounts Receivable | €17.99 Billion | 19.3% |
| Inventory | €21.21 Billion | 22.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €13.94 Billion | 14.9% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Fuji Pharma Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fuji Pharma Co. Ltd's current assets represent 51.3% of total assets in 2025, a decrease from 67.7% in 2014.
- Cash Position: Cash and equivalents constituted 7.8% of total assets in 2025, down from 16.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 9.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 22.7% of total assets.
Fuji Pharma Co. Ltd Competitors by Total Assets
Key competitors of Fuji Pharma Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Fuji Pharma Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Fuji Pharma Co. Ltd generates 0.55x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Fuji Pharma Co. Ltd generates $ 3.21 in net profit.
Fuji Pharma Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.55 | 1.31 | 3.18 |
| Quick Ratio | 0.86 | 0.66 | 2.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €16.93 Billion | € 9.34 Billion | € 23.97 Billion |
Fuji Pharma Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Fuji Pharma Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.14 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 3.8% |
| Total Assets | €93.41 Billion |
| Market Capitalization | $142.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values Fuji Pharma Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Fuji Pharma Co. Ltd's assets grew by 3.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Fuji Pharma Co. Ltd (2014–2025)
The table below shows the annual total assets of Fuji Pharma Co. Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | €93.41 Billion | +3.78% |
| 2024-09-30 | €90.00 Billion | +5.47% |
| 2023-09-30 | €85.33 Billion | +12.97% |
| 2022-09-30 | €75.54 Billion | +17.59% |
| 2021-09-30 | €64.24 Billion | +3.67% |
| 2020-09-30 | €61.96 Billion | +2.02% |
| 2019-09-30 | €60.74 Billion | +14.35% |
| 2018-09-30 | €53.12 Billion | +7.20% |
| 2017-09-30 | €49.55 Billion | +2.92% |
| 2016-09-30 | €48.15 Billion | +5.19% |
| 2015-09-30 | €45.77 Billion | -6.64% |
| 2014-09-30 | €49.03 Billion | -- |